Clinical trials are prompting doctors in Spain to advocate for prioritizing heart health over solely focusing on weight loss when prescribing medications like semaglutide or tirzepatide. These drugs, used for obesity treatment, have demonstrated a significant benefit: a 20% reduction in the risk of serious cardiovascular events. Notably, this benefit extends even to individuals who do not have diabetes. The findings suggest the drugs offer cardioprotective effects independent of weight loss. This has led to calls for a more comprehensive evaluation of patients, focusing on cardiac health alongside body weight. Experts believe a broader assessment will ensure optimal patient care and recognize the full potential of these medications in Spain. The research underscores a shifting perspective on obesity treatment towards a holistic approach encompassing cardiovascular well-being.